• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Accessing health outcome data on high-cost medicines in Australia.

作者信息

Lu Christine Y, Williams Kenneth M, Day Richard O

机构信息

Faculty of Medicine, Department of Clinical Pharmacology, University of New South Wales, Sydney, NSW.

出版信息

Med J Aust. 2006 Apr 17;184(8):411-3. doi: 10.5694/j.1326-5377.2006.tb00293.x.

DOI:10.5694/j.1326-5377.2006.tb00293.x
PMID:16618242
Abstract

Data on health outcomes resulting from the use of medicines provide important evidence of cost-effectiveness. Currently, clinical information on individual patients, collected by Medicare Australia to assess eligibility for subsidised treatment with high-cost medicines, is inaccessible for research. Comprehensive data on drug use and health outcomes should be made accessible, with appropriate regulation, so that the effectiveness, utility and appropriateness of our systems of access to medicines can be independently analysed. In the interests of continuous improvement in medical care and optimal use of limited resources, we strongly advocate the enhancement of Medicare Australia databases and liberalisation of arrangements for access to administrative and clinical data.

摘要

相似文献

1
Accessing health outcome data on high-cost medicines in Australia.
Med J Aust. 2006 Apr 17;184(8):411-3. doi: 10.5694/j.1326-5377.2006.tb00293.x.
2
Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.两国患者获取药品情况比较:卫生体制相似,药品政策不同——基于全面文献回顾的结果
Res Social Adm Pharm. 2019 Mar;15(3):231-243. doi: 10.1016/j.sapharm.2018.04.006. Epub 2018 Apr 13.
3
Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis.通过泰国的E2获取计划扩大高成本药品的可及性:采用中断时间序列分析对药品使用、健康结果及成本的影响
BMJ Open. 2016 Mar 17;6(3):e008671. doi: 10.1136/bmjopen-2015-008671.
4
Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?
Health Policy. 2014 Jun;116(2-3):234-5. doi: 10.1016/j.healthpol.2014.01.014. Epub 2014 Jan 28.
5
How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.《跨太平洋伙伴关系协定如何损害 PHARMAC 并威胁新西兰平价药品的可及性和医疗公平性》
Health Policy. 2013 Oct;112(3):227-33. doi: 10.1016/j.healthpol.2013.07.021. Epub 2013 Aug 30.
6
A national analysis of dental waiting lists and point-in-time geographic access to subsidised dental care: can geographic access be improved by offering public dental care through private dental clinics?一项关于牙科等候名单及获得补贴牙科护理的即时地理可达性的全国性分析:通过私立牙科诊所提供公共牙科护理能否改善地理可达性?
Rural Remote Health. 2017 Jan-Mar;17(1):3814. doi: 10.22605/rrh3814. Epub 2017 Jan 12.
7
Look beyond budgets to the broader benefits.
Healthc Pap. 2002;3(1):77-82; discussion 87-94. doi: 10.12927/hcpap..16914.
8
How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.如何解决融资缺口以确保中东欧国家的患者能够获得专利药品?——好的、坏的及丑陋的方式。
Expert Rev Pharmacoecon Outcomes Res. 2019 Dec;19(6):627-632. doi: 10.1080/14737167.2019.1702524. Epub 2019 Dec 10.
9
Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake.透过澳大利亚参议院调查视角看高成本癌症药物的获取——界定利益相关的“商品”
J Bioeth Inq. 2017 Sep;14(3):401-410. doi: 10.1007/s11673-017-9800-2. Epub 2017 Jul 18.
10
Managing healthcare costs within an integrated framework.在综合框架内管理医疗成本。
Healthc Pap. 2002;3(1):70-6; discussion 87-94. doi: 10.12927/hcpap..16913.

引用本文的文献

1
Patient access schemes in Asia-pacific markets: current experience and future potential.亚太市场的患者准入计划:当前经验与未来潜力
J Pharm Policy Pract. 2015 Feb 16;8(1):6. doi: 10.1186/s40545-014-0019-x. eCollection 2015.
2
Access to high cost medicines in Australia: ethical perspectives.澳大利亚高价药品的获取:伦理视角
Aust New Zealand Health Policy. 2008 May 19;5:4. doi: 10.1186/1743-8462-5-4.
3
The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.澳大利亚高成本药品的资金投入与使用:以抗风湿生物药为例。
Aust New Zealand Health Policy. 2007 Mar 1;4:2. doi: 10.1186/1743-8462-4-2.